215 related articles for article (PubMed ID: 38191367)
21. Dual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications.
Fourneaux B; Chaire V; Lucchesi C; Karanian M; Pineau R; Laroche-Clary A; Italiano A
Oncotarget; 2017 Jan; 8(5):7878-7890. PubMed ID: 28002802
[TBL] [Abstract][Full Text] [Related]
22. Disruption of the RICTOR/mTORC2 complex enhances the response of head and neck squamous cell carcinoma cells to PI3K inhibition.
Ruicci KM; Plantinga P; Pinto N; Khan MI; Stecho W; Dhaliwal SS; Yoo J; Fung K; MacNeil D; Mymryk JS; Barrett JW; Howlett CJ; Nichols AC
Mol Oncol; 2019 Oct; 13(10):2160-2177. PubMed ID: 31393061
[TBL] [Abstract][Full Text] [Related]
23. Angiogenin interacts with ribonuclease inhibitor regulating PI3K/AKT/mTOR signaling pathway in bladder cancer cells.
Peng Y; Li L; Huang M; Duan C; Zhang L; Chen J
Cell Signal; 2014 Dec; 26(12):2782-92. PubMed ID: 25193113
[TBL] [Abstract][Full Text] [Related]
24. Synergistic targeted inhibition of MEK and dual PI3K/mTOR diminishes viability and inhibits tumor growth of canine melanoma underscoring its utility as a preclinical model for human mucosal melanoma.
Wei BR; Michael HT; Halsey CH; Peer CJ; Adhikari A; Dwyer JE; Hoover SB; El Meskini R; Kozlov S; Weaver Ohler Z; Figg WD; Merlino G; Simpson RM
Pigment Cell Melanoma Res; 2016 Nov; 29(6):643-655. PubMed ID: 27463366
[TBL] [Abstract][Full Text] [Related]
25. Pharmacogenomic profiling of the PI3K/PTEN-AKT-mTOR pathway in common human tumors.
Xu G; Zhang W; Bertram P; Zheng XF; McLeod H
Int J Oncol; 2004 Apr; 24(4):893-900. PubMed ID: 15010827
[TBL] [Abstract][Full Text] [Related]
26. [Study of gambogenic acid-induced apoptosis of melanoma B16 cells through PI3K/Akt/mTOR signaling pathways].
Cheng H; Zhang X; Su JJ; Li QL
Zhongguo Zhong Yao Za Zhi; 2014 May; 39(9):1666-9. PubMed ID: 25095381
[TBL] [Abstract][Full Text] [Related]
27. TDRG1 regulates chemosensitivity of seminoma TCam-2 cells to cisplatin via PI3K/Akt/mTOR signaling pathway and mitochondria-mediated apoptotic pathway.
Gan Y; Wang Y; Tan Z; Zhou J; Kitazawa R; Jiang X; Tang Y; Yang J
Cancer Biol Ther; 2016 Jul; 17(7):741-50. PubMed ID: 27104982
[TBL] [Abstract][Full Text] [Related]
28. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
[TBL] [Abstract][Full Text] [Related]
29. PI3K/AKT/mTOR pathway inhibitors inhibit the growth of melanoma cells with mTOR H2189Y mutations in vitro.
Wu X; Yu J; Yan J; Dai J; Si L; Chi Z; Sheng X; Cui C; Ma M; Tang H; Xu T; Yu H; Kong Y; Guo J
Cancer Biol Ther; 2018 Jul; 19(7):584-589. PubMed ID: 29708815
[TBL] [Abstract][Full Text] [Related]
30. Abnormal Protein Glycosylation and Activated PI3K/Akt/mTOR Pathway: Role in Bladder Cancer Prognosis and Targeted Therapeutics.
Costa C; Pereira S; Lima L; Peixoto A; Fernandes E; Neves D; Neves M; Gaiteiro C; Tavares A; Gil da Costa RM; Cruz R; Amaro T; Oliveira PA; Ferreira JA; Santos LL
PLoS One; 2015; 10(11):e0141253. PubMed ID: 26569621
[TBL] [Abstract][Full Text] [Related]
31. Suppression of PI3K/Akt/mTOR/c-Myc/mtp53 Positive Feedback Loop Induces Cell Cycle Arrest by Dual PI3K/mTOR Inhibitor PQR309 in Endometrial Cancer Cell Lines.
Hsin IL; Shen HP; Chang HY; Ko JL; Wang PH
Cells; 2021 Oct; 10(11):. PubMed ID: 34831139
[TBL] [Abstract][Full Text] [Related]
32. Increased activation of PI3K/AKT signaling pathway is associated with cholangiocarcinoma metastasis and PI3K/mTOR inhibition presents a possible therapeutic strategy.
Yothaisong S; Dokduang H; Techasen A; Namwat N; Yongvanit P; Bhudhisawasdi V; Puapairoj A; Riggins GJ; Loilome W
Tumour Biol; 2013 Dec; 34(6):3637-48. PubMed ID: 23832540
[TBL] [Abstract][Full Text] [Related]
33. Melatonin combined with endoplasmic reticulum stress induces cell death via the PI3K/Akt/mTOR pathway in B16F10 melanoma cells.
Kim HS; Kim TJ; Yoo YM
PLoS One; 2014; 9(3):e92627. PubMed ID: 24647338
[TBL] [Abstract][Full Text] [Related]
34. Label-free-based quantitative proteomic analysis of the inhibition of cisplatin-resistant ovarian cancer cell proliferation by cucurbitacin B.
Yin S; Mai Z; Liu C; Xu L; Xia C
Phytomedicine; 2023 Mar; 111():154669. PubMed ID: 36681055
[TBL] [Abstract][Full Text] [Related]
35. Exogenous hydrogen sulfide inhibits human melanoma cell development via suppression of the PI3K/AKT/ mTOR pathway.
Xiao Q; Ying J; Qiao Z; Yang Y; Dai X; Xu Z; Zhang C; Xiang L
J Dermatol Sci; 2020 Apr; 98(1):26-34. PubMed ID: 32098704
[TBL] [Abstract][Full Text] [Related]
36. Oncogenic DNA methyltransferase 1 activates the PI3K/AKT/mTOR signalling by blocking the binding of HSPB8 and BAG3 in melanoma.
Yang Y; Ma S; Ye Z; Zheng Y; Zheng Z; Liu X; Zhou X
Epigenetics; 2023 Dec; 18(1):2239607. PubMed ID: 37523636
[TBL] [Abstract][Full Text] [Related]
37. Features of the reversible sensitivity-resistance transition in PI3K/PTEN/AKT signalling network after HER2 inhibition.
Goltsov A; Faratian D; Langdon SP; Mullen P; Harrison DJ; Bown J
Cell Signal; 2012 Feb; 24(2):493-504. PubMed ID: 21996585
[TBL] [Abstract][Full Text] [Related]
38. Targeting PI3K-AKT-mTOR by LY3023414 inhibits human skin squamous cell carcinoma cell growth in vitro and in vivo.
Zou Y; Ge M; Wang X
Biochem Biophys Res Commun; 2017 Aug; 490(2):385-392. PubMed ID: 28623128
[TBL] [Abstract][Full Text] [Related]
39. Knocking down FAM83B inhibits endometrial cancer cell proliferation and metastasis by silencing the PI3K/AKT/mTOR pathway.
Lin Q; Chen H; Zhang M; Xiong H; Jiang Q
Biomed Pharmacother; 2019 Jul; 115():108939. PubMed ID: 31079003
[TBL] [Abstract][Full Text] [Related]
40. Eribulin Synergistically Increases Anti-Tumor Activity of an mTOR Inhibitor by Inhibiting pAKT/pS6K/pS6 in Triple Negative Breast Cancer.
Wen W; Marcinkowski E; Luyimbazi D; Luu T; Xing Q; Yan J; Wang Y; Wu J; Guo Y; Tully D; Han ES; Yost SE; Yuan Y; Yim JH
Cells; 2019 Aug; 8(9):. PubMed ID: 31480338
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
